Please find below the nineteenth Ximbio product update. This month’s mailer details fourteen new monoclonal antibodies and one protein available for licence or purchase.
For licensing and sales enquiries please email: enquiries@ximbio.com or call +44 (0)20 3469 6449.
Technical datasheets for Ximbio’s expanding research tool portfolio can be accessed at www.ximbio.com
Applications: FACS IF Fn
Reactivity: Human CD195 or CCR5 (CC-chemokine receptor type 5) is a receptor for a number of inflammatory CC-chemokines including MIP-1-alpha, MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. It may play a role in the control of granulocytic lineage proliferation or differentiation, and has been shown to act as a co-receptor for HIV-1 R5 isolates. Recent studies have shown CCR5 to play a role in a variety of other human diseases, ranging from infectious and inflammatory diseases to cancer.
|
|
Applications: IHC IF
Mouse monoclonal antibody generated against flavivirus envelope proteins. Recognizes Dengue virus, West Nile Virus, Japanese Encephalitis and Zika virus. It binds to domain II of protein E (fusion loop).
|
|
Applications: IHC ELISA WB
Influenza virus nucleoprotein (NP) is a structural protein which encapsulates the negative strand viral RNA. NP is one of the main determinants of species specificity. Monoclonal HB65 is a classic reagent for the detection of flu virus particles. It can be used for IP, WB and IHC including formalin fixed tissue sections.
|
|
Applications: IHC ELISA WB
The human immunodeficiency virus (HIV) surface glycoprotein 120 (gp120) attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. |
|
Applications: ELISA FACS IHC WB
Reactivity: Human
CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas.Since 2011 treatments targeting CD19 have begun to enter trials. Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers. However, it is now emerging that the protein plays an active role in driving the growth of these cancers, most intriguingly by stabilizing the concentrations of the myc oncoprotein. This suggests that CD19 and its downstream signaling may be a more attractive therapeutic target than originally thought.CD19 has also been implicated in autoimmune diseases and may be a useful treatment target.
|
|
Applications: ELISA FACS IHC WB
Reactivity: Human
CD20 is the target of the monoclonal antibodies (mAb) rituximab, obinutuzumab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemia. It has been shown that inhibition of BCR signalling by ibrutinib affects the expression of CD20 and the efficacy of anti-CD20 antibodies.
|
|
Reactivity: Human
Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including squamous-cell carcinoma of the lung, anal cancers, glioblastoma and epithelial tumors of the head and neck. These somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division. In glioblastoma a more or less specific mutation of EGFR, called EGFRvIII is often observed. Mutations, amplifications or misregulations of EGFR or family members are implicated in about 30% of all epithelial cancers. Monoclonal 225, also known as Cetuximab, is a chimeric (mouse/human) monoclonal antibody and widely used in tumor therapy with more than 100 published references.
|
|
Applications: IHC IF WB
Reactivity: Human, Mouse, Rabbit, Xenopus laevis and Zebrafish
Hu proteins are RNA-binding proteins involved in diverse biological processes. The individual members Hel-N1(HuB), HuC, and HuD play important roles in neuronal differentiation and plasticity. The expression of these proteins serves as an excellent neuronal marker. These proteins are typically found in the nucleus, but can be transported to the cytoplasm. The classic monoclonal antibody (16A11) used to identify these proteins only identifies the cytoplasmic fraction. Whereas this recombinant humanized monoclonal recognizes the major nuclear fraction of HuD/HuC and Hel-N1. Thus it has the potential to uncover new biological functions and associations.
|
|
Anti-HuD/HuC/HuB [8B3] (RIP/CHIP Grade)
Applications: ChIP ELISA IHC IF WB
Reactivity: Human
HuD otherwise known as ELAV-like protein 4 is a protein that in humans is encoded by the ELAVL4 gene. The HuD/ELAVL4 protein is an RNA-binding protein. HuD is expressed only in neurons and it binds to AU-rich element-containing mRNAs. As a result of this interaction the half-life of the transcript is increased. HuD is important in neurons during brain development and plasticity. Monoclonal to HuB, HuC and HuD but not to HuA (HuR).
|
|
Applications: ELISA IHC IF WB
Reactivity: Human HuD otherwise known as ELAV-like protein 4 is a protein that in humans is encoded by the ELAVL4 gene. The HuD/ELAVL4 protein is an RNA-binding protein. HuD is expressed only in neurons and it binds to AU-rich element-containing mRNAs. As a result of this interaction the half-life of the transcript is increased. HuD is important in neurons during brain development and plasticity. The 16A11 anti-HuD monoclonal is now a classic reagent for the identification of neurons.
|
|
Anti-HuD [15A9] (ChIP Grade)
Applications: ChIP ELISA IHC IP WB
Reactivity: Human
Monoclonal 15A9 was generated against a unique HuD peptide and does not react with HuR, HuC, or Hel-N1. Monoclonal 15A9 works well in western blot, IHC and provides an excellent marker for neuronal cells. However, it was specifically selected becasue of its abiity to supershift HuD/mRNA ribonucleoprotein complexes. Thus, it is the ideal reagent for CHIP or RIP studies to specifically identify novel HuD targets in neuronal cells.
|
|
Applications: ELISA IHC WB
Reactivity: Human, Mouse, Rat and Zebrafish The 16C12 monoclonal antibody is the reagent of choice to determine the expression of HuD (ELAVL4) by IHC or western blotting. It is known to react with human, mouse, rat, and zebrafish HuD. It was generated against a unique peptide found in HuD and does not bind to HuC, HeLN-1 or HuR.
|
|
Applications: ELISA IP
Reactivity: Human
Sucrase-isomaltase is a glucosidase enzyme and type II transmembrane glycoprotein located in on the brush border of the small intestine and preferentially expressed in the apical membranes of enterocytes. Sucrase-isomaltase digests dietary carbohydrates like starch, glucose, and isomaltose, which enables further processing of metabolites to form energy in the form of ATP. Defects in sucrase-isomaltase are the cause of the disease; congenital sucrase-isomaltase deficiency also known as disaccharide intolerance I. This an autosomal recessive intestinal disorder that is clinically characterized by abdominal pain, fermentative diarrhea and cramping.
|
|
Applications: IHC WB
Reactivity: Human
The cytoskeleton in keratinocytes is a complex of highly homologous structural proteins derived from two families of type I and type II polypeptides. Keratin K2e is a type II polypeptide that is expressed in epidermis late in differentiation. K2e expression in skin is sensitive to keratinocyte activation but its up-regulation in oral lesions is a reflection of the degree of orthokeratinization.
|
|
HuD otherwise known as ELAV-like protein 4 is a protein that in humans is encoded by the ELAVL4 gene. The HuD/ELAVL4 protein is an RNA-binding protein. HuD is expressed only in neurons and it binds to AU-rich element-containing mRNAs. As a result of this interaction the half-life of the transcript is increased. HuD is important in neurons during brain development and plasticity. HuD was originaly discovered as the paraneoplastic antigen expressed in neuroendocrine tumors. Recombinant HuD was first used to assay the presence of anti-Hu antibodies and thereby diagnose the presence of small cell lung cancer and subacute sensory neuronopathy.
|
|